MRNA
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
Article Summary
BUY- Moderna Inc. (NASDAQ: MRNA) announced expanded collaboration with Coalition for Epidemic Preparedness Innovations to advance development of potential vaccine against Bundibugyo ebolavirus, a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.
- Under agreement, CEPI committed up to US $50 million to support preclinical development and Phase 1 clinical testing of investigational BDBV vaccine candidate, with funding also supporting parallel manufacturing activities positioning program to rapidly advance into large-scale Phase 2/3 trials if Phase 1 safety and immunogenicity data support further development.
- Vaccine candidate is being developed using Moderna's mRNA platform, same technology that demonstrated rapid development, scalability, and global deployment capabilities during COVID-19 pandemic, with program also building on existing research and development efforts in filoviruses including Ebola-related viruses.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -30.0% | 25% | 0.0 ptsDeclining (-30.0%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 26.3% | 25% | 80.0 ptsVery Good (26.3%) - Good outlook |
| Target Price Upside ? | 0.6% | 20% | 10.0 ptsNear/At Target (0.6%) - Target: $46.80 vs Current: $47.10 |
| Gross Margin % ? | 11.6% | 15% | 20.0 ptsThin (11.6%) - Low-margin business |
| Drawdown from 52-Wk High ? | -20.9% | 15% | 40.0 ptsMild Pullback (-20.9%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MRNA
- Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
- The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
- It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
- It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
- The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
- Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.